|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
����ͷ������ |
|
���� |
|
��ͻ״ϸ�� |
| ��������������� | |
|
«���� |
|
�̺� |
| PubMed | |
|
Article by |
|
Article by |
��ͻ״ϸ��Ϊ������������HPV��Ⱦ�����е�Ӧ��ǰ��
«����, �̺�
�㽭��ѧҽѧԺ�������ݷ�ҽԺ ���� 310016
��ͻ״ϸ���ǹ�����ǿ�Ŀ�ԭ���ϸ��,������Tϸ������Ӧ������ؼ�����.����ͻ״ϸ��Ϊ����������ͷ�������������������鼰����ģ������֤ʵ������������ϸ������T�ܰ�ϸ����Ӧ��Ⱦ���������.�־���ͻ״ϸ���Ĺ��ܡ����ԡ��ٴ�Ӧ�ü���ͻ״ϸ�������ڷ�������ͷ��������Ⱦ�е��о���״��һ����.
[2] Ressing ME,Sette A,Brandi RM,et al.Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding pepfides.J Im-munol,1995,154(11):5934-5943.
[3] Ulmer JB,Donnelly JJ,Parker SE,et al.Heterologens protection against irdtuenza by injection of DNA encoding a viral protein.Science,1993,259(5102):1745-1749.
[4] Tuting T,DeLeo AB,Lotze MT,et al.Genetically modified bone marrow-derived dendritic cells expressing tumor-asseciated viral or "self" antigens induce antitonwr immunity in vivo.Eur J Immunol,1997,27(10):2702-2707.
[5] Tillman BW,Hayes TL,DeGruijl TD,et al.Adanoviral vectors targeted to CI40 enhance the efficacy of dendritic cell-based vaccination against human papillcomavirus 16-induced tumor cells in a murine model.Cancer Res,2000,60(19):5456-5463.
[6] Ji H,Wang TL,Chen CH,et al.Targeting human papillomaviros type 16 E7 to the endosemal/lysesomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors.Hum Gene Ther,1999,10(17):2727-2740.
[7] Tbomborg C,Boczkowski D,Gilboa E,et al.Induction of cytotoxic T lymphocytes with dendritic cells transfected with human papillomavirns E6 and E7 RNA:implications for cervical cancer immunotherapy.J Immunother,2000,23(4):412-418.
[8] Cheng WF,Hung CF,Hsu KF,et al.Enhancement of sindbis vires self-replicating RNA vaccine potency by targeting antigen to endosomal/lyseso-real compartmens.Hum Gene Ther,2001,12(3):235-252.
[9] Santin AD,Hermonat PL,Ravaggi A,et al.Induction of human papillo-mavims-specific CIM(+) and CD8(+) lymphecytes by E7-polsed autol-ngans dendritic cells in patients with human papillomavirus type 16-and 18-positive cervical cancer.J Virol,1999,73(7):5402-5410.
[10] Murakami M,Gurski KJ,Marincola FM,et al.Induction of specific CD8+ T-lymphocyte responses using a human papillomavims-16 E6/E'/fusion protein and antologeus dendritic cells.Cancer Res,1999,59(6):1184-1187.
[11] De Bruijn ML,Schuurhuis DH,Vierboom MP,et al.hranunization with human papillomavirus type 16(HPV16) oncoprotein-lceded dandritic cells as well as protein in adjuvant induces MHC class ��-restricted protection to HPV16-induced tumor cells.Cancer Res,1998,58(4):724-731.
[12] Feltkamp MC,Vrougdenhil GR,Vierbnem MP,et al.Cytotoxic T lyraphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors.Eur J Immunol,1995,25(9):2638-2642.
[13] Wang TL,Ling M,Shih IM,et al.Intramuscular administratian of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor inmmunity.Gene Ther,2000,7(9):726-733.
[14] Indrova M,Bubonik J,Simova J,et al.Therapy of HPV 16-asseciated carcinoma with dendritic cell-based vaccines:in vitro priming of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide.Int J Mol Med,2001,7(1):97-100.
[15] Greenstone HL,Nieland JD,de Visser KE,et al.Chimeric papillomavims vires-like particles elicit antitumor immunity against the E7 oncoprotein inan HPV16 tumor model.Proc Nail Acad Sci U S A,1998,95(4):1800-1805.
[16] Cain JM,Howett MK.Preventing cervical cancer.Science,2000,288(5472):1753-1755.
[17] Lenz P,Day PM,Pang YY,et al.Papillomavims-like particles induce acute activation of dendritic cells.J Immunol,2001,166(9):5346-5355.
[18] Kanfmann AM,Nieland J,Schinz M,et al.HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination.Int J Cancer,2001,92(2):285-293.
[19] Lucey DR,Clerici M,Shearer GM.Type 1 and type 2 cytokine dysregu-lation in human infectious,neoplastic,and inflammatory diseases.Clin Microbiol Rev,1996,9(4):532-562.
[20] Cao X,Ju DW,Tan Q,et al.Adenovirns-medinted GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorneytosine administration elicit more potent antitumor response in tumor-bearing mice.Gene Ther,1998,5(8):1130-1136.
[21] Cao X,Zhang W,Wang J,et al.Therapy of established tumonr with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.Immunology,1999,97(4):616-625.
[22] Tyring SK.Human papillomavims infections:epidemiology,pathogenesis,and host immune response.J Am Acad Dermatol,2000,43(1 Pt 2):S18-26.
[23] Vaquer S,Jorda J,Lopes de la Osa E,et al.Clinical implications of natural killer(NK) cytotoxicity in patients with squamons cell carcinoma of the uterine cervix.Gynecol Oncel,1990,36(1):90-92.